1-3 of 3
Mirjana Sirovica
Close
Sort by
Journal Articles

Vaccination with a DNA and MVA ‘Prime-Boost’ Regimen Induces Strong CD8 + T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial

Charlotte F Inman, BVSc, PhD, Suzy A Eldershaw, BSc. (Hons.), PhD, Hayden Pearce, BSc. (Hons.), PhD, Ben E Abbotts, BSc. (Hons.), MSc., Mirjana Sirovica, BSc(Hons), MSc, Paul Ferguson, MD PhD MRCP, Donna L Walsh, Dip(HE), BSc., Jane Nunnick, BSC. (Hons.), MSc., Shamyla Siddique, BSc.(Hons.), MPhil, Paul Moss, MBBS, PhD FRCP, Ram K Malladi, FRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 1908.
https://doi.org/10.1182/blood.V130.Suppl_1.1908.1908
Published: 2017
Journal Articles

Reduced Intensity Stem Cell Transplantation Followed By Adjunctive Lenalidomide Is Tolerable and Safe and Improves Complete Response Rate in Multiple Myeloma:a UK NCRI Phase 2 Feasibility Study (LenaRIC)

Mark Cook, MBChB,PhD, Anesh Panchal, BSc, MSc, Kristian Brock, MSc, BSc, Grant McQuaker, MD, John A. Snowden, MD, Charles R Crawley, Hannah Hunter, MB,FRCPath,MRCP, James D Cavenagh, Mirjana Sirovica, BSc(Hons), MSc, Andrea Hodgkinson, BSc(Hons),PhD, Gordon Cook, MD PhD FRCP, FRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 3308.
https://doi.org/10.1182/blood.V130.Suppl_1.3308.3308
Published: 2017
Journal Articles

Immune Biomarkers Identify Sustained Quantitative and Functional Immune Reconstitution in the Setting of Adjunctive Lenalidomide Following T-Depleted RIC-Allo SCT for Multiple Myeloma

Gordon Cook, MD PhD, Clive R Carter, PhD, Kristian Brock, MSc, BSc, Grant McQuaker, MD, John A Snowden, Charles Crawley, Hannah Hunter, Jamie D. Cavenagh, Mark Lobb, BSc(Hons), Katherine Cullen, BSc, MSc, Andrea Hodgkinson, Mirjana Sirovica, Mark Cook, PhD MBChB
Journal: Blood
Blood (2016) 128 (22): 4585.
https://doi.org/10.1182/blood.V128.22.4585.4585
Published: 2016